Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
vTv Therapeutics Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26 | Direct | 19,555 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 19,555 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 20:09 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 6,000 | $35.08 Strike: $35.08 | $210,480.00 |
DisclosureSEC source: 0001928247-26-000003 · wk-form4_1782763744.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,555 Underlying: Class A Common Stock · 6,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:25 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 4,000 | $16.59 Strike: $16.59 | $66,360.00 |
DisclosureSEC source: 0001641489-25-000040 · wk-form4_1749759899.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,555 Underlying: Class A Common Stock · 4,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:38 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 3,000 | $17.22 Strike: $17.22 | $51,660.00 |
DisclosureSEC source: 0001641489-24-000049 · wk-form4_1719520722.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,555 Underlying: Class A Common Stock · 3,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The options will vest on the one-year anniversary of the date of grant Read SEC document |
| February 27, 2024 Filed Jun 13, 2024 20:42 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 4,055 | $11.81 Strike: $11.81 | $47,889.55 |
DisclosureSEC source: 0001641489-24-000042 · wk-form4_1718311314.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,555 Underlying: Class A Common Stock · 4,055 shares Expires 2034-02-27 F1 · derivative.exercise_date: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 20:21 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001641489-23-000036 · wk-form4_1687378854.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A Common Stock · 75,000 shares Expires 2033-06-19 F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0000950142-22-002216 · es220270155_4-almarzooqi.xml · derivative · entry 1 Al-Marzooqi Fahed · CIK 0001928247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2032-07-13 F1 · derivative.exercise_date: Vests on July 13, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.